FEATURED ARTICLES
Everyone Talks About Site Selection — But Few Actually Get It Right
The site selection process is complicated by outdated data, limited operational insight, and overreliance on reputation. Discover some practical ways to evaluate site feasibility for your next trial.
-
Sites Are 3X Likely To Die In The First Year Than New Businesses
Milken Institute Health Director of Research Andrew Friedson, Ph.D., reveals the stark truth of site survivability and discusses how factors like available population and local economic conditions factor into survival rates.
-
Sponsors Collect Too Much "Non-Essential" Data, Say Tufts And TransCelerate
A collaboration between Tufts CSDD, Tufts School of Medicine, and TransCelereate BioPharma revealed just how much extra data sponsors are collecting — and why that's a problem.
-
Participant Recruitment In LMIC Clinical Trials
Due to the high burden of infectious diseases in low- and middle-income countries (LMICs), there is greater urgency for vaccine trials. Participant recruitment entails significant work with communities.